Published on 15 Feb 2024 on Zacks via Yahoo Finance
When C4 Therapeutics, Inc. CCCC reports fourth-quarter and full-year 2023 results, investors will primarily focus on pipeline updates.
The company has a decent track record of beating on earnings in three of the trailing four quarters and missing in one, delivering an average surprise of 5.04%. In the last reported quarter, it delivered an earnings surprise of 15.38%.
C4 Therapeutics, Inc. Price, Consensus and EPS Surprise